ArticleCurrent treatment options in cardiovascular medicine2013
Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women?
Article in Current treatment options in cardiovascular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Estrogen stimulates SREBP2 expression in hepatic cell lines via an estrogen response element in the SREBP2 promoter.Cellular & molecular biology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementAlthough the US Preventive Services Task Force and other contemporary guidelines recommend that Menopausal Hormone Therapy (MHT) not be used for prevention of chronic conditions, its use for prevention of cardiovascular disease remains controversial. The Women's Health Initiative and the Heart and Estrogen/progestin Replacement Study explored the benefits and risks of MHT for cardiovascular disease, primary and secondary prevention respectively, but challenges to these data include suboptimal hormone therapy adherence and the advanced age of the women at initiation of MHT. Here we discuss the recent literature impacting MHT management of the peri- and post-menopausal women who are concerned about cardiovascular disease risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.